Exact Sciences Corp. (NASDAQ:EXAS) traded up 4% on Wednesday . The stock traded as high as $12.33 and last traded at $12.33, with a volume of 1,748,326 shares. The stock had previously closed at $11.86.

Several equities research analysts have weighed in on the company. Zacks Investment Research raised Exact Sciences Corp. from a “hold” rating to a “buy” rating and set a $8.25 price target for the company in a report on Tuesday, April 26th. Mizuho downgraded Exact Sciences Corp. from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $12.00 to $6.50 in a report on Wednesday, May 4th. BTIG Research reaffirmed a “buy” rating and set a $9.00 target price on shares of Exact Sciences Corp. in a report on Tuesday, May 24th. Jefferies Group reaffirmed a “buy” rating on shares of Exact Sciences Corp. in a report on Wednesday, May 4th. Finally, William Blair reaffirmed a “buy” rating on shares of Exact Sciences Corp. in a report on Wednesday, June 15th. Eight equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $10.17.

The stock’s market capitalization is $1.18 billion. The company has a 50 day moving average of $8.85 and a 200 day moving average of $7.28.

Exact Sciences Corp. (NASDAQ:EXAS) last announced its earnings results on Tuesday, May 3rd. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.03. The firm earned $14.80 million during the quarter, compared to analyst estimates of $15.17 million. During the same period last year, the company earned ($0.40) earnings per share. The firm’s revenue for the quarter was up 244.2% compared to the same quarter last year. On average, equities analysts predict that Exact Sciences Corp. will post ($2.00) EPS for the current fiscal year.

Other hedge funds recently bought and sold shares of the company. Eagle Asset Management bought a new stake in Exact Sciences Corp. during the third quarter worth $39,880,000. California State Teachers Retirement System boosted its stake in Exact Sciences Corp. by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 177,702 shares of the company’s stock worth $1,640,000 after buying an additional 2,809 shares during the last quarter. OppenheimerFunds Inc. boosted its stake in Exact Sciences Corp. by 455.5% in the fourth quarter. OppenheimerFunds Inc. now owns 2,777,430 shares of the company’s stock worth $25,636,000 after buying an additional 2,277,430 shares during the last quarter. Finally, US Bancorp DE boosted its stake in Exact Sciences Corp. by 2.3% in the fourth quarter. US Bancorp DE now owns 229,594 shares of the company’s stock worth $2,119,000 after buying an additional 5,109 shares during the last quarter.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.